SCHEMBL1187191

SCHEMBL1187191

CCOC(=O)CC1(NC(=O)c2ccccc2)CCC1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.49
HSD17B10 Q99714 2/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
KMT2A Q03164 2/20 0.45
TSHR P16473 2/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
ADAM17 P78536 1/20 0.42
CTSL P07711 1/20 0.42
CTSK P43235 1/20 0.41
ATM Q13315 1/20 0.41
MEN1 O00255 1/20 0.41
PPID Q08752 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10607221 0.84 ADRB2 (0.57) ADRB2HSD17B10KMT2AALDH1A1GAA
SCHEMBL1186102 0.81 ADRB2 (0.57) ADRB2HSD17B10SMN1; SMN2KMT2AALDH1A1
SCHEMBL28022532 0.79 ADRB2 (0.47) ADRB2HSD17B10SMN1; SMN2KMT2AALDH1A1
SCHEMBL10604253 0.79 ADRB2 (0.55) ADRB2HSD17B10KMT2AALDH1A1GAA
SCHEMBL1187444 0.79 ADRB2 (0.55) ADRB2HSD17B10KMT2AALDH1A1GAA
SCHEMBL18314645 0.78 ADRB2 (0.52) ADRB2HSD17B10KMT2AALDH1A1GAA
SCHEMBL1757278 0.77 ADRB2 (0.63) ADRB2KMT2AALDH1A1GAAL3MBTL1
SCHEMBL10604425 0.76 ADRB2 (0.52) ADRB2HSD17B10CTSLCTSK
SCHEMBL7434481 0.76 PPID (0.53) HSD17B10SMN1; SMN2KMT2AALDH1A1GAA
SCHEMBL6101144 0.75 LMNA (0.51) SMN1; SMN2KMT2AALDH1A1GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2203459-B1 SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS KYORIN SEIYAKU KK (JP) 2016-03-16 EP disclosed
EP-2203459-B1 SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS KYORIN SEIYAKU KK (JP) 2016-03-16 EP disclosed
CN-102344457-B Spirocyclic aminoquinolones as GSK-3 inhibitors KYORIN SEIYAKU KK 2015-07-22 CN disclosed
US-8901112-B2 Spirocyclic aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2014-12-02 US disclosed
US-8901112-B2 Spirocyclic aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2014-12-02 US disclosed
US-8901112-B2 Spirocyclic aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2014-12-02 US disclosed
US-20140005184-A1 SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS KYORIN PHARMACEUTICALS CO., LTD. (JP) 2014-01-02 US disclosed
US-8476261-B2 Spirocyclic aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2013-07-02 US disclosed
US-8476261-B2 Spirocyclic aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2013-07-02 US disclosed
US-8476261-B2 Spirocyclic aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2013-07-02 US disclosed
CN-102344457-A Spirocyclic aminoquinolones as gsk-3 inhibitors KYORIN SEIYAKU KK 2012-02-08 CN disclosed
US-20110034436-A1 SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-02-10 US disclosed
US-20110034436-A1 SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-02-10 US disclosed
CN-101855229-A Spirocyclic aminoquinolones as GSK-3 inhibitors ACTIVX BIOSCIENCES INC 2010-10-06 CN disclosed
EP-2203459-A1 SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS Activx Biosciences, Inc. (US) 2010-07-07 EP disclosed
WO-2009035684-A1 SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS ACTIVX BIOSCIENCES, INC. (US) 2009-03-19 WO disclosed
WO-2009035684-A1 SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS ACTIVX BIOSCIENCES, INC. (US) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140005184-A1 SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS GSK3A, GSK3B, GSKIP ADRB2 2207/4885HSD17B10 600/4885SMN1; SMN2 3945/4885
US-20110034436-A1 SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS GSK3A, GSK3B, GSKIP ADRB2 325/4885HSD17B10 409/4885SMN1; SMN2 4161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.